Rovsing A/S
Interim Management Statement covering Q3 2024/25
Interim Management Statement covering Q3 2024/25
Interim Management Statement covering Q3 2024/25
The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the third quarter (1 January 2025– 31 March 2025) of the financial year 2024/25.
Q3 highlights
- In Q3 2024/25, the revenue amounted to DKK 7.5 million (Q3 2023/24: DKK 9.5 million).
- EBITDA in Q3 amounted to DKK -0.4 million (Q3 2023/24: DKK 0.8 million).
- Order intake in Q3 amounted to DKK 9.3 million. During Q3 and to date, the Company signed new contracts for the ESA EnVision mission with prime contractor Thales Alenia Space and a new commercial contract with The Exploration Company for the Independent Software Validation and Verification (ISVV) of the software for their modular & reusable NyX space vehicle. Total order intake in the period January until end of April amounts to DKK 23.6 million.
- As of today, the Company maintains a healthy and diverse order backlog of DKK 48.3 million, ranging across several different missions and customers in both institutional, military and commercial space, making for a solid foundation for the Company’s operations in the coming fiscal year.
- Management and the Board of Directors have continued to work in line with the updated strategy for Rovsing with the focus on the main themes: Growth, Diversification, Competitiveness, and Investor Relations.
- During Q3 2024/25, our team has continued to support a wide range of customers, delivering test- and simulation systems, individual products, software solutions, Independent Software Validation & Verification (ISVV) and on-site engineering services. Our team is hard at work delivering projects and milestones to our customers, having shipped several Electrical Ground Support Equipment (EGSE) systems recently and with more to follow during the coming months, across customers and segments.
- The Company anticipates a high activity level in Q4 and maintains the outlook for 2024/25, with a revenue in the range of DKK 37.0 to 40.0 million and a positive EBITDA in the range of DKK 1.0 to 2.0 million.
Further information:
Hjalti Pall Thorvardarson, CEO. Tel. +45 53 39 18 88. Email: hpt@rovsing.dk
Attachments
- Selskabsmeddelelse383_Kvartalsmeddelelse_Q3_2024-25-DK
- Announcement383_Interim_Management_Statement_Q3_2024-25
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S21.6.2025 01:38:10 CEST | Press release
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Novo Nordisk A/S21.6.2025 01:34:39 CEST | Press release
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Meeting Professionals International (MPI)21.6.2025 01:30:16 CEST | Press release
MPI Shares WEC 2025 Highlights, Announces Strategic Growth and New Offerings at Annual Press Conference
Leading Edge Materials Corp.20.6.2025 23:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO APRIL 30, 2025
Aduro Clean Technologies Inc.20.6.2025 22:33:57 CEST | Press release
Aduro Clean Technologies Announces Closing of Underwriter’s Over-Allotment Option in Public Offering
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom